Factors associated with death during tuberculosis treatment of patients co-infected with HIV at the Yaoundé Central Hospital, Cameroon: An 8-year hospital-based retrospective cohort study (2006-2013)

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Agbor, Ako A ^a   Bigna, Jean Joel R ^b   Billong, Serges Clotaire ^a,b   Tejiokem, Mathurin Cyrille ^c,d   Ekali, Gabriel L ^b   Plottel, Claudia S ^e,f   Noubiap, Jean Jacques N ^g   Abessolo, Hortence ^h   Toby, Roselyne ^h   Koulla Shiro, Sinata ^a,h  

^a UNIVERSITY OF YAOUNDÉ I   (Cameroon)

^b MINISTRY OF PUBLIC HEALTH   (Cameroon)

^c CENTRE PASTEUR DU CAMEROUN   (Cameroon)

^d International Network of the Pasteur Institute   (France)

^e NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^f NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g Internal Medicine Unit Edea Regional Hospital   (Cameroon)

^h YAOUNDÉ CENTRAL HOSPITAL   (Cameroon)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; COTRIMOXAZOLE; TUBERCULOSTATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AGED; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CAMEROON; COHORT ANALYSIS; COMORBIDITY; DEATH; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MORTALITY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; TREATMENT FAILURE; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS CONTROL; ADOLESCENT; AIDS RELATED COMPLEX; CAUSE OF DEATH; COMPLICATION; EPIDEMIOLOGY; HOSPITAL; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTITUBERCULAR AGENTS; CAMEROON; CAUSE OF DEATH; COHORT STUDIES; COINFECTION; COMORBIDITY; FEMALE; HOSPITALS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT FAILURE; TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION; TUBERCULOSIS; YOUNG ADULT;

EID: 84919489954     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0115211     Document Type: Article

References (47)

1. Sunderam G, McDonald RJ, Maniatis T, Oleske J, Kapila R, et al. (1986) Tuberculosis as a manifestation of the acquired immunodeficiency syndrome (AIDS). 256: 362-366.
2. Quinn TC, Mann JM, Curran JW, Piot P (2001) AIDS in Africa: an epidemiologic paradigm. 1986. Bull World Health Organ 79: 1159-1167.
3. Friedland G, Churchyard GJ, Nardell E (2007) Tuberculosis and HIV coinfection: current state of knowledge and research priorities. J Infect Dis 196 Suppl 1: S1-3.
4. UNAIDS (2013) Global Report: UNAIDS report on the global AIDS epidemic 2013. UNAIDS. Available: http://www.unaids.org/en/media/unaids/contentassets/documents/epidemiology/2013/gr2013/UNAIDS-Global-Report-2013-en.pdf. Accessed 2014 Nov 24.
5. World Health Organization (2011) Global tuberculosis control: WHO report 2011. Geneva, Switzerland: World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/44728/1/9789241564380-eng.pdf?ua=1. Accessed 2014 Nov 24.
6. Harries AD (2000) Issues facing TB control (6). Tuberculosis control in sub-Saharan Africa in the face of HIV and AIDS. Scott Med J 45: 47-50; discussion 51.
7. Kuaban C, Pefura E, Bava D, Onana I (2011) Early mortality in new patients on treatment for smear positive pulmonary tuberculosis in Yaounde-Cameroon. Health Sciences and Diseases 12.
8. Ansari NA, Kombe AH, Kenyon TA (2002) Pathology and causes of death in a group of 128 predominantly HIV-positive patients in Botswana, 1997-1998. Int J Tuberc Lung Dis 6: 55-63.
9. Programme National de lutte contre la Tuberculose (2014) Plan stratégique de lutte contre la tuberculose au Cameroun 2015-2019. Yaoundé, Cameroon: Programme National de lutte contre la Tuberculose. Available: http://www.pnlt.cm/index.php/documentation/plan-strategique-national/doc-download/18-plan-strategique-natinal-tuberculose-cameroun. Accessed 2014 Nov 24.
10. World Health Organization (2013) Global tuberculosis report 2013. Geneva, Switzerland: World Health Organization. Available: http://apps.who.int/iris/bitstream/10665/91355/1/9789241564656-eng.pdf. Accessed 2014 Nov 24.
11. Sume GE, Hoshen M, Bita G, Kabore S, Nzima VN (2009) Treatment outcome of TB/HIV positive and negative smear positive pulmonary tuberculosis patients treated using daily self-administered therapy in a Cameroonian district hospital. East Afr Med J 86: 469-475.
12. Banerjee A, Moyo S, Salaniponi F, Harries A (1997) HIV testing and tuberculosis treatment outcome in a rural district in Malawi. Trans R Soc Trop Med Hyg 91: 707-708.
13. van den Broek J, Mfinanga S, Moshiro C, O'Brien R, Mugomela A, et al. (1998) Impact of human immunodeficiency virus infection on the outcome of treatment and survival of tuberculosis patients in Mwanza, Tanzania. Int J Tuberc Lung Dis 2: 547-552.
14. El-Sony AI, Khamis AH, Enarson DA, Baraka O, Mustafa SA, et al. (2002) Treatment results of DOTS in 1797 Sudanese tuberculosis patients with or without HIV co-infection. Int J Tuberc Lung Dis 6: 1058-1066.
15. Zachariah R, Spielmann MP, Harries AD, Salaniponi FML (2002) Moderate to severe malnutrition in patients with tuberculosis is a risk factor associated with early death. Trans Roy Soc Trop Med Hyg 96: 291-294.
16. Sileshi B, Deyessa N, Girma B, Melese M, Suarez P (2013) Predictors of mortality among TB-HIV Coinfected patients being treated for tuberculosis in Northwest Ethiopia: a retrospective cohort study. BMC Infect Dis 13: 297.
17. Connolly C, Reid A, Davies G, Sturm W, McAdam KP, et al. (1999) Relapse and mortality among HIV-infected and uninfected patients with tuberculosis successfully treated with twice weekly directly observed therapy in rural South Africa. AIDS 13: 1543-1547.
18. Shaweno D, Worku A (2012) Tuberculosis treatment survival of HIV positive TB patients on directly observed treatment short-course in Southern Ethiopia: a retrospective cohort study. BMC Res Notes 5: 682.
19. Programme National de lutte contre la Tuberculose (2012) Guide pour les personnels de santé. Yaoundé, Cameroon: Ministry of Public Health of Cameroon. Available: http://www.pnlt.cm/index.php/documentation/rapports-d-activites/cat-view/4-guidetechnique?orderby=dmdatecounter&ascdesc=DESC. Accessed 2014 Nov 24.
20. Rubin D, Schenker N (1991Apr) Multiple imputation in health-care databases: an overview and some applications. Statistics in medicine 10: 585-598.
21. Little RJ, Rubin DB (1987) Statistical Analysis With Missing Data: Wiley.
22. Kuaban C, Bercion R, Koulla-Shiro S (1997) HIV seroprevalence rate and incidence of adverse skin reactions in adults with pulmonary tuberculosis receiving thiacetazone free anti-tuberculosis treatment in Yaounde, Cameroon. East Afr Med J 74: 474-477.
23. Pefura Yone EW, Kuaban C, Kengne AP (2012) HIV testing, HIV status and outcomes of treatment for tuberculosis in a major diagnosis and treatment centre in Yaounde, Cameroon: a retrospective cohort study. BMC Infect Dis 12: 190.
24. Yone EW, Kuaban C, Kengne AP (2012) [Impact of HIV infection on the evolution of tuberculosis among adult patients in Yaounde, Cameroon]. Rev Pneumol Clin 68: 338-344.
25. Ifebunandu NA, Ukwaja KN, Obi SN (2012) Treatment outcome of HIV-associatedtuberculosis in a resource-poor setting. Trop Doct 42: 74-76.
26. Shastri S, Naik B, Shet A, Rewari B, De Costa A (2013) TB treatment outcomes among TB-HIV coinfections in Karnataka, India: how do these compare with non-HIV tuberculosis outcomes in the province? BMC Public Health 13: 838.
27. Ismail I, Bulgiba A (2013) Predictors of death during tuberculosis treatment in TB/HIV co-infected patients in Malaysia. PLoS One 8: e73250.
28. Rizzardi GP, Pantaleo G (1999) The immunopathogenesis of HIV-sa1 infection. In: Armstrong D, Cohen J, editors. Infectious diseases. London: Harcourt. pp.1-12.
29. Nakata K, Rom WN, Honda Y, Condos R, Kanegasaki S (1997) Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication in the lung. Am J Respir Crit Care Med 155: 996-1003.
30. Zhang Y, Nakata K, Weiden M, Rom WN (1995) Mycobacterium tuberculosis enhances human immunodeficiency virus-1 replication by transcriptionalactivation at the long terminal repeat. J Clin Invest 95: 2324-2331.
31. Connolly C, Davies GR, Wilkinson D (1998) Impact of human immunodeficiency virus epidemic on mortality among adults with tuberculosis in rural South Africa. Int J Tuberc Lung Dis 2: 919-925.
32. Harries AD, Nyangulu DS, Kang'Ombe C, Ndalama D, Glynn JR, et al. (1998) Treatment outcome of an unselected cohort of tuberculosis patients in relation to human immunodeficiency virus serostatus in Zomba hospital, Malawi. Trans Roy Soc Trop Med Hyg 92: 343-347.
33. Kantipong P, Murakami K, Moolphate S, Aung MN, Yamada N (2012) Causes of mortality among tuberculosis and HIV co-infected patients in Chiang Rai, Northern Thailand. HIV/AIDS - Research and Palliative Care 4: 159-168.
34. Harries AD, Zachariah R, Lawn SD (2009) Providing HIV care for coinfected tuberculosis patients: a perspective from sub-Saharan Africa. Int J Tuberc Lung Dis 13.
35. Witor SZ (1999) Efficacy of trimethroprim-sulphamethoxazole (co-trimoxazole) prophylaxis to decrease morbidity and mortality in HIV-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomized controlled trial The Lancet 353: 1469-1475.
36. Mwaungulu FB, Floyd S (2004 May) Cotrimoxazole prophylaxis reduces mortality in human immunodeficiency virus-positive tuberculosis patients in Kagora District, Malawi Bull WorldHealth Organ 82: 354-363.
37. Kirenga BJ, Levin J, Ayakaka I, Worodria W, Reilly N, et al. (2014) Treatment outcomes of new tuberculosis patients hospitalized in Kampala, Uganda: a prospective cohort study. PLoS One 9: e90614.
38. Blanc FX, Sok T, Laureillard D, Borand L, Rekacewicz C, et al. (2011) Earlier versus later start of antiretroviral therapy in HIV-infected adults with tuberculosis. N Engl J Med 365: 1471-1481.
39. National AIDS Control Committtee (2010) National Guidelines for the Management of HIV Infection in Adults and Adolescents. Yaoundé, Cameroon: Ministry of Public of Health.
40. Mungrue K, Beharry A, Kalloo J, Mahabir S, Maraj T, et al. (2009) Trends in HIV/TB coinfection in Trinidad and Tobago for the period 1998-2007. J Int Assoc Physicians AIDS Care (Chic) 8: 170-175.
41. Hoffmann C (2007) Opportunistic Infections: In Bernd Sebastian Kamps, ed. HIV Medicine. Paris: Flying Publisher. pp.389-477.
42. Kohli R, Lo Y, Howard AA, Buono D, Floris-Moore M, et al. (2005) Mortality in an urban cohort of HIV-infected and at-risk drug users in the era of highly active antiretroviral therapy. Clin Infect Dis 41: 864-872.
43. Dou ZH, Zhao Y, He Y, He WS, Ji GP, et al. (2009) [A retrospective cohort study on reduction of AIDS mortality among patients enrolled in national-free antiretroviral treatment programme in two cities in China]. Zhonghua Yu Fang Yi Xue Za Zhi 43: 1091-1095.
44. Sun DY, Wang Q, Yang WJ, Zhu Q, Wang Z (2012) [Survival analysis on AIDS antiretroviral therapy in Henan province during 2003-2009]. Zhonghua Liu Xing Bing Xue Za Zhi 33: 181-184.
45. Marcy O, Laureillard D, Madec Y, Chan S, Mayaud C, et al. (2014) Causes and determinants of mortality in HIV-infected adults with tuberculosis: an analysis from the CAMELIA ANRS 1295-CIPRA KH001 randomized trial. Clin Infect Dis 59: 435-445.
46. Cox H, Hughes J, Daniels J, Azevedo V, McDermid C, et al. (2014) Community-based treatment of drug-resistant tuberculosis in Khayelitsha, South Africa. Int J Tuberc Lung Dis 18: 441-448.
47. Alvarez-Uria G, Midde M, Pakam R, Naik PK (2013) Diagnostic and Prognostic Value of Serum Albumin for Tuberculosis in HIV Infected Patients Eligible for Antiretroviral Therapy: Datafrom an HIV Cohort Study in India. Bioimpacts 3: 123-128.